1,205 results match your criteria Current Cancer Drug Targets[Journal]


An integrative "omics" approach, for identification of bona fides PLK1 associated biomarker in Oesophgeal adenocarcinoma.

Curr Cancer Drug Targets 2019 Feb 10. Epub 2019 Feb 10.

Edinburgh Cancer Research Center, University of Edinburgh. United Kingdom.

Background: The rapid expansion of genome wide profiling techniques offers the opportunity to utilize various types of information collectively in the study of human health and disease. Overexpression of Polo like kinase 1 (PLK1) is associated with oesophageal adenocarcinoma (OAC), however biological functions and molecular targets of PLK1 in OAC are still unknown.

Objectives: Here we performed integrative analysis of two "omics" data sources to reveal high level interactions of PLK1 associated with OAC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190211113722DOI Listing
February 2019

Anti-cancer effects of curcumin on myelodysplastic syndrome through the inhibition of enhancer of zeste homolog-2 (EZH2).

Curr Cancer Drug Targets 2019 Feb 12. Epub 2019 Feb 12.

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030. China.

Enhancer of zeste homolog-2 (EZH2), a histone methyltransferase that regulates histone H3 methylation of lysine27 (H3K27me3), is involved in the pathogenesis of myelodysplastic syndrome (MDS). Targeting epigenetic regulators has been identified as a potential treatment target in MDS chemotherapy. Curcumin, a natural compound extracted from turmeric, was found to possess a wide range of anticancer activities in various tumors. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/169909/article
Publisher Site
http://dx.doi.org/10.2174/1568009619666190212121735DOI Listing
February 2019
2 Reads

Autophagy And Apoptosis Specifc Knowledgebases-Guided Systems Pharmacology Drug Research.

Curr Cancer Drug Targets 2019 Feb 6. Epub 2019 Feb 6.

School of Pharmacy, University of Pittsburgh, 335 Sutherland Drive, 206 Salk Pavilion. United States.

Backgrounds: Autophagy and apoptosis are the basic physiological processes in cells that clean up aged and mutant cellular components or even the entire cells. Both autophagy and apoptosis are disrupted in most major diseases such as cancer and neurological disorders. Recently, increasing attention is paid to understand the crosstalk between autophagy and apoptosis due to their tightly synergetic or opposite functions in several pathological processes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190206122149DOI Listing
February 2019

Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.

Curr Cancer Drug Targets 2019 Feb 6. Epub 2019 Feb 6.

Department of Urology, Huashan Hospital Affiliated to Fudan University, Shanghai. China.

Background: Malignant pheochromocytoma (mPCC) is an uncommon tumor with poor prognosis, and no effective therapeutic strategy exists. Discovering new and effective therapeutic strategies to improve prognosis is an urgent need.

Objective: To investigate whether combinatorial inhibition of both mTORC2 and Hsp90 in PC12 cells could lead to a distinctly antitumor effect in vitro and in vivo that was greater than inhibition of mTORC2 or Hsp90 alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190206120615DOI Listing
February 2019
1 Read

The clinical prognostic value of LRG1 in esophageal squamous cell carcinoma.

Curr Cancer Drug Targets 2019 Feb 3. Epub 2019 Feb 3.

Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan, Shandong. China.

Background: Leucine-rich-alpha-2-glycoprotein1 (LRG1) is a new oncogene-related gene, which has been verified important to the development and poor prognosis of human cancers. However, whether it participates in esophageal squamous cell carcinoma (ESCC) progression remains unclear.

Objective: To investigate the expression level and functional influence of LRG1 in ESCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190204095942DOI Listing
February 2019

Targeted Nanotechnology from Bench to Bedside.

Curr Cancer Drug Targets 2019 ;19(1):3-4

Department of Pharmacology & Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156800961901181204130142DOI Listing
January 2019
1 Read

Preface.

Authors:
Ruiwen Zhang

Curr Cancer Drug Targets 2019 ;19(1)

Professor of Pharmacology and Toxicology (Tenured) Robert L. Boblitt Endowed Professor in Drug Discovery Director of UH Drug Discovery Institute University of Houston, Houston, TX 77204, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156800961901181204125705DOI Listing
January 2019

Zoledronic Acid Inhibits the RhoA-mediated Amoeboid Motility of Prostate Cancer Cells.

Curr Cancer Drug Targets 2019 Jan 15. Epub 2019 Jan 15.

Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Viale Morgagni 50, 50142 Firenze. Italy.

Background: The bisphosphonate Zoledronic acid (ZA) is a potent osteoclast inhibitor currently used in the clinic to reduce osteoporosis and cancer-induced osteolysis. Moreover, ZA exerts an anti-tumor effect in several tumors. Despite this evidence, the relevance of ZA in prostate cancer (PCa) is not completely understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190115142858DOI Listing
January 2019
1 Read

Isolation, solid-state structure determination, in silico and in vitro anticancer evaluation of an indole amino acid alkaloid L-Abrine†.

Curr Cancer Drug Targets 2019 Jan 10. Epub 2019 Jan 10.

Department of Chemistry, The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, Texas - 78539. United States.

Background: Abrus precatorius Linn. (Kunch in Bengali) is widely spread in tropical and sub-tropical regions. It is a typical plant species which is well-known simultaneously as folk medicine and for its toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190111111937DOI Listing
January 2019
1 Read

Gefitinib represses JAK-STAT signaling activated by CRTC1-MAML2 fusion in mucoepidermoid carcinoma cells.

Curr Cancer Drug Targets 2019 Jan 3. Epub 2019 Jan 3.

Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, 450008. China.

Background: Gefitinib is well-known as a tyrosine kinase inhibitor targeting non-small-lung-cancer (NSCLC) containing EGFR mutations. However, its effectiveness in treating mucoepidermoid carcinoma (MEC) without such EGFR mutations suggests additional targets.

Objective: The CRTC1-MAML2 (C1-M2) fusion typical for MEC has been proposed to be a gefitinib target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666190103122735DOI Listing
January 2019
1 Read
3.522 Impact Factor

EH-42, a novel small molecule induces apoptosis and inhibits migration and invasion of human hepatoma cells through suppressing STAT3 signaling pathway.

Curr Cancer Drug Targets 2018 Dec 25. Epub 2018 Dec 25.

Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009. China.

Background: Since signal transducer and activator of transcription 3 (STAT3) is aberrantly activated in hepatocellular carcinoma (HCC) and plays a key role in this tumor progression, inhibition of the STAT3 signaling pathway has been considered as an effective therapeutic strategy for suppressing HCC development.

Objective: In this study, we investigated the anti-cancer effects of EH-42 on HCC cells and tried to explain the underlying mechanism.

Methods: MTT assay, colon formation assay and AnnexinV-FITC/PI double-staining assay were performed to assess the effects of EH-42 on cell growth and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666181226094814DOI Listing
December 2018
1 Read

Nanotherapy Targeting the Tumor Microenvironment.

Curr Cancer Drug Targets 2018 Dec 19. Epub 2018 Dec 19.

Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai, 200433. China.

Cancer is characterized by high mortality and low curability. Recent studies have shown that the mechanism of tumor resistance involves not only endogenous changes to tumor cells, but also to the tumor microenvironment (TME), which provides the necessary conditions for the growth, invasion, and metastasis of cancer cells, akin to Stephen Paget's hypothesis of "seed and soil." Hence, the TME is a significant target for cancer therapy via nanoparticles, which can carry different kinds of drugs targeting different types or stages of tumors. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/168480/article
Publisher Site
http://dx.doi.org/10.2174/1568009619666181220103714DOI Listing
December 2018
11 Reads

Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.

Curr Cancer Drug Targets 2018 Dec 9. Epub 2018 Dec 9.

Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe. Japan.

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancers. Indeed, gefitinib, which was the first molecular targeted therapeutic agent, has actually doubled the survival time of NSCLC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666181210114559DOI Listing
December 2018
1 Read

Mesoporous silica nanoparticles as a prospective and promising approach for drug delivery and biomedical applications.

Curr Cancer Drug Targets 2018 Dec 5. Epub 2018 Dec 5.

Institute of Materia Medica, School of Pharmacy, Henan University, Jinming Road, Kaifeng, 475004. China.

Background: With the development of nanotechnology, nanocarrier has widely applied in such fields as drug delivery, diagnostic and medical imaging and engineering in recent years. Among all of the available nanocarrier, mesoporous silica nanoparticles (MSNs) have become a hot issue because of their unique properties, such as large surface area and voidage, tunable drug loading capacity and release kinetics, good biosafety and easily modified surface.

Objectives: We described the most recent progress in silica-assisted drug delivery and biomedical applications according to different types of Cargo in order to allow researchers to quickly learn about of the advance in this field. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666181206114904DOI Listing
December 2018
2 Reads
3.522 Impact Factor

Insilico structure modeling and molecular docking analysis of phosphoribosyl pyrophosphate amidotransferase (PPAT) with antifolate inhibitors.

Curr Cancer Drug Targets 2018 Nov 26. Epub 2018 Nov 26.

King Fahd Medical Research Center, King Abdulaziz University, P. O. Box 80216, Jeddah 21589. Saudi Arabia.

Cancer remains the one most serious disease worldwide. Robust metabolism is hallmark of the cancer. PPAT (phosphoribosyl pyrophosphate amidotransferase) catalyzes the first committed step of de novo purine biosynthesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666181127115015DOI Listing
November 2018
9 Reads
3.522 Impact Factor

Inhibition of the ATPase domain of human topoisomerase IIa on HepG2 cells by 1, 2-benzenedicarboxylic acid, mono (2-ethylhexyl) ester: molecular docking and dynamics simulations.

Curr Cancer Drug Targets 2018 Nov 27. Epub 2018 Nov 27.

School of Biosciences and Technology, VIT University, Vellore, Tamil Nadu. India.

Background: The major attention has been received by the natural products in the prevention of diseases due to their pharmacological role.

Objective: The major focus of the study was to search for highly potential anti-cancer compounds from marine Streptomyces sp. VITJS4 (NCIM No. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009619666181127122230DOI Listing
November 2018
9 Reads

Overexpression of Nemo-like kinase promotes the proliferation and invasion of lung cancer cells and indicates poor prognosis.

Curr Cancer Drug Targets 2018 Nov 19. Epub 2018 Nov 19.

Department of Pathology, College of Basic Medical Sciences and the First Hospital, China Medical University, Shenyang 110001. China.

Nemo-like kinase (NLK) is an evolutionarily conserved MAP kinase-related kinase involved in the pathogenesis of several human cancers. We examined the expression of NLK in lung cancer tissues through western blot analysis. We enhanced or knocked down NLK expression by gene transfection or RNA interference, respectively, in lung cancer cells and examined expression alterations of key proteins in the Wnt signaling pathway and in epithelial-mesenchymal transition (EMT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181119150521DOI Listing
November 2018
8 Reads

Bone invasive properties of oral squamous cell carcinoma and its interactions with alveolar bone cells: an in vitro study.

Curr Cancer Drug Targets 2018 Nov 2. Epub 2018 Nov 2.

Cancer Molecular Pathology, School of Medicine, Griffith University, Gold Coast, Queensland. Australia.

Background: Co-culture of cancer cells with alveolar bone cells could modulate bone invasion and destructions. However, the mechanisms of interaction between oral squamous cell carcinoma (OSCC) and bone cells remain unclear.

Objective: The aim of this study is to analyse the direct and indirect effects of OSCC cells in the stimulation of osteolytic activity and bone invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181102144317DOI Listing
November 2018
12 Reads

Characterization of YY1 OPB Peptide for Its Anticancer Activity.

Curr Cancer Drug Targets 2018 Oct 31. Epub 2018 Oct 31.

Department of Cancer Biology and Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston-Salem, NC 27157. United States.

The oncoprotein binding (OPB) domain of Yin Yang 1 (YY1) consists of 26 amino acids between G201 and S226, and is involved in YY1 interaction with multiple oncogene products, including MDM2, AKT, EZH2 and E1A. Through the OPB domain, YY1 promotes the oncogenic or proliferative regulation of these oncoproteins in cancer cells. We previously demonstrated that a peptide with the OPB sequence blocked YY1-AKT interaction and inhibited breast cancer cell proliferation. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166836/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181031153151DOI Listing
October 2018
10 Reads

CT-707 Overcomes Resistance of crizotinib through activating PDPK1-AKT1 pathway by targeting FAK.

Curr Cancer Drug Targets 2018 Oct 31. Epub 2018 Oct 31.

Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, 100021. China.

Background: Crizotinib established the position of anaplastic lymphoma kinase-tyrosine kinase inhibitors (ALK-TKI) in the treatment of non-small cell lung cancer(NSCLC) while the therapy-resistance hindered those patients from benefitting continuously from the treatment. CT-707 is an inhibitor of ALK/focal adhesion kinase (FAK) and IGFR-1. H2228CR (crizotinib resistance, CR) and H3122CR NSCLC cell lines were generated from the parental cell line H2228 (EML4-ALK, E6a/b:A20, variant 3) and H3122(EML4-ALK, E13:A20, variant 1), respectively. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166834/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181031152140DOI Listing
October 2018
7 Reads

The RNA Binding Protein HuR: a Promising Drug Target for Anticancer Therapy.

Curr Cancer Drug Targets 2018 Oct 31. Epub 2018 Oct 31.

Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR. China.

The stability of mRNA is one of the key factors governing the regulation of eukaryotic gene expression and function. Human antigen R (HuR) is a RNA-binding protein that regulates the stability, translation, and nucleus-to-cytoplasm shuttling of its target mRNAs. While HuR is normally localized within the nucleus, it has been shown that HuR binds mRNAs in the nucleus and then escorts the mRNAs to the cytoplasm where HuR protects them from degradation. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166832/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181031145953DOI Listing
October 2018
3 Reads

Targeting strategies for glucose metabolic pathways and T cells in colorectal cancer.

Curr Cancer Drug Targets 2018 Oct 15. Epub 2018 Oct 15.

Department of Medicine, Jiangsu University, Zhenjiang City, Jiangsu Province 212001. China.

Colorectal cancer is a heterogeneous group of diseases that result from the accumulation of different sets of genomic alterations, together with epigenomic alterations, and it is influenced by tumor-host interactions, leading to tumor cell growth and glycolytic imbalances. This review summarizes recent findings that involve multiple signaling molecules and downstream genes in the dysregulated glycolytic pathway. This paper further discusses the role of the dysregulated glycolytic pathway in the tumor initiation, progression and the concomitant systemic immunosuppression commonly observed in colorectal cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181015150138DOI Listing
October 2018
8 Reads

Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors.

Curr Cancer Drug Targets 2018 Oct 18. Epub 2018 Oct 18.

Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Jaén. Spain.

Background: Brain tumorigenesis is related to oxidative stress and a decreased response of antioxidant defense systems. Due to it is well known that gender differences exists in the incidence and survival rates of brain tumors, it is important to recognize and understand the ways in which their biology can differ.

Objective: To analyze gender differences in redox status in animals with chemically-induced brain tumors. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166440/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181018162549DOI Listing
October 2018
7 Reads

HSF1 as a Cancer Biomarker and Therapeutic Target.

Curr Cancer Drug Targets 2018 Oct 18. Epub 2018 Oct 18.

Melvin and Bren Simon Cancer Center, Indiana University School of Medicine, Bloomington, IN 47405. United States.

Heat shock factor 1 (HSF1) was discovered in 1984 as the master regulator of the heat shock response. In this classical role, HSF1 is activated following cellular stresses such as heat shock that ultimately lead to HSF1-mediated expression of heat shock proteins to protect the proteome and survive these acute stresses. However, it is now becoming clear that HSF1 also plays a significant role in several diseases, perhaps none more prominent than cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181018162117DOI Listing
October 2018
9 Reads

Targeting Upstream Kinases of STAT3 in Human Medulloblastoma cells.

Curr Cancer Drug Targets 2018 10 16. Epub 2018 Oct 16.

Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA

Background: Medulloblastoma is the most common malignant brain tumor in children. Despite improvement in overall survival rate, it still lacks an effective targeted treatment strategy. The Janus family of cytoplasmic tyrosine kinases (JAKs) and Src kinases, upstream protein kinases of signal transducer and activator of transcription 3 (STAT3), play important roles in medulloblastoma pathogenesis and therefore represent potential therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181016165604DOI Listing
October 2018
27 Reads
3.522 Impact Factor

The Multifunctional Protein p62 and Its Mechanistic Roles in Cancers.

Curr Cancer Drug Targets 2018 Oct 16. Epub 2018 Oct 16.

Division of Infectious Diseases, Department of Internal Medicine, Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614. United States.

The multifunctional signaling hub p62 is well recognized as ubiquitin sensor and selective autophagy adaptor under myriad stress conditions including cancer. As a ubiquitin sensor, p62 promotes NFκB activation by facilitating TRAF6 ubiquitination and aggregation. As a selective autophagy receptor, p62 links ubiquitinated substrates including p62 itself for lysosome-mediated degradation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181016164920DOI Listing
October 2018
25 Reads
3.522 Impact Factor

Osimertinib quantitative and gene variation analyses in cerebrospinal fluid and plasma of non-small cell lung cancer patient with leptomeningeal metastases.

Curr Cancer Drug Targets 2018 Oct 17. Epub 2018 Oct 17.

Department of Medical Oncology, Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/ Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences , Beijing 100021. China.

Background: Leptomeningeal metastases (LM) are much more frequent in patients of non-small lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. Osimertinib, a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) shows promising efficacy for LM.

Objective: The aim of this study was to analyze the concentration of osimertinib and gene variation of circulating tumor DNA (ctDNA) in human plasma and cerebrospinal fluid (CSF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181017114111DOI Listing
October 2018
10 Reads

Oral Drug Delivery Systems for Ulcerative Colitis Therapy: A Comparative Study with Microparticles and Nanoparticles.

Curr Cancer Drug Targets 2018 Oct 16. Epub 2018 Oct 16.

Institute for Clean Energy and Advanced Materials, Faculty of Materials and Energy, Southwest University, Chongqing. China.

Background: Oral administrations of microparticles (MPs) and nanoparticles (NPs) have been widely explored as therapeutic approaches for treatment of ulcerative colitis (UC). However, no previous study has comparatively investigated the therapeutic efficacy of MPs and NPs.

Methods: In this study, curcumin (CUR)-loaded MPs (CUR-MPs) and CUR-loaded NPs (CUR-NPs) were fabricated using an emulsion-solvent evaporation method. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166312/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181016152042DOI Listing
October 2018
2 Reads

Ursolic acid in cancer treatment and metastatic chemoprevention: from synthesized derivatives to nanoformulations in preclinical studies.

Curr Cancer Drug Targets 2018 Oct 16. Epub 2018 Oct 16.

Cancer Metastasis Alert and Prevention Center, Pharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, and Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy, College of Chemistry, Fuzhou University, Fuzhou 350116. China.

Background: Cancer metastasis has emerged as a major public health threat that cause majority of cancer fatalities. Traditional chemotherapeutics have been effective in the past but suffer from low therapeutic efficiency and harmful side-effects. Recently, it has been reported ursolic acid (UA), one of the naturally abundant pentacyclic triterpenes, possesses a wide range of biological activities including anti-inflammatory, anti-atherosclerotic, and anti-cancer properties. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181016145940DOI Listing
October 2018
1 Read

Gene Therapy and Photothermal Therapy of Layer-by-Layer Assembled AuNCs /PEI/miRNA/ HA Nanocomplexes.

Curr Cancer Drug Targets 2018 Oct 16. Epub 2018 Oct 16.

Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Henan Province; School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou 450001. China.

MicroRNA (miRNA) therapy, which was widely considered to treat a series of cancer, has been confronted with numerous obstacles to being delivered into target cells because of its easy biodegradation and instability. In this research, we successfully constructed 11-mercaptoundecanoic acid modified gold nanocages (AuNCs)/polyethyleneimine (PEI)/miRNA/hyaluronic acid (HA) complexes (abbreviated as AuNCs/PEI/miRNA/HA) using a layer-by-layer method for target-specific intracellular delivery of miRNA by HA receptor mediated endocytosis. The results of UV spectra, hydrodynamic diameter and zeta potential analyses confirmed the formation of AuNCs/PEI/miRNA/HA complex with its average particle size of ca. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666181016144855DOI Listing
October 2018
4 Reads

Targeting Membrane Receptors of Ovarian Cancer Cells for Therapy.

Curr Cancer Drug Targets 2018 Oct 9. Epub 2018 Oct 9.

School of Pharmacy, Jiangsu University, Zhenjiang, Jiangsu 212013. China.

Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, survival has improved little over the last 20 years. The management of patients with ovarian cancer also remains similar despite studies showing striking differences and heterogeneity among different subtypes. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/166111/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181010091246DOI Listing
October 2018
4 Reads

The Association of Neuronal Stress with Activating Transcription Factor 3 in Dorsal Root Ganglion of in vivo and in vitro Models of Bortezomib- Induced Neuropathy.

Curr Cancer Drug Targets 2019 ;19(1):50-64

Department of Anatomy, Shandong University School of Basic Medical Sciences, Jinan 250012, China.

Background: The notion that proteasome inhibitor bortezomib (BTZ) induced intracellular oxidative stress resulting in peripheral neuropathy has been generally accepted. The association of mitochondrial dysfunction, cell apoptosis, and endoplasmic reticulum (ER) stress with intracellular oxidative stress is ambiguous and still needs to be investigated. The activation of activating transcription factor 3 (ATF3) is a stress-hub gene which was upregulated in dorsal root ganglion (DRG) neurons after different kinds of peripheral nerve injuries. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165929/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666181003170027DOI Listing
January 2019
2 Reads

In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells.

Curr Cancer Drug Targets 2018 Sep 10. Epub 2018 Sep 10.

Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmaceutical Sciences, Tianjin Medical University, Tianjin 300070. China.

Background: Metastasis is the main cause of lethality of prostate cancer. Inhibition of metastasis is expected to be a promising approach for prostate cancer therapy. Phosphatidylinositol 3-kinase (PI3K)/Akt pathway is known to play key roles in cell growth, migration, etc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180911101310DOI Listing
September 2018
11 Reads

Cordycepin downregulates Cdk-2 to interfere with cell cycle and increases apoptosis by generating ROS in cervical cancer cells: in vitro and in silico study.

Curr Cancer Drug Targets 2018 Sep 4. Epub 2018 Sep 4.

Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000. China.

Cordycepin is a small molecule from medicinal mushroom Cordyceps, which has been reported for anticancer properties. In this study, we investigated cordycepin effect on cervical cancer cells in vitro. Results indicate that treatment of cordycepin controlled SiHa and Hela cervical cancer cell growth, increased the rate of their apoptosis, and interfered with cell cycle, specifically elongated S-phase. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165124/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666180905095356DOI Listing
September 2018
8 Reads
3.522 Impact Factor

c-Myc inhibitor 10074-G5 induces murine and human hematopoietic stem and progenitor cell expansion and HDR modulator Rad51 expression.

Curr Cancer Drug Targets 2018 Sep 4. Epub 2018 Sep 4.

Yeditepe University - Genetics and Bioengineering Department Istanbul. Turkey.

c-Myc plays a major role in the maintenance of glycolytic metabolism and hematopoietic stem cell (HSC) quiescence. Targeting modulators of HSC quiescence and metabolism could lead to HSC cell cycle entry with concomitant expansion. Here we show that c-Myc inhibitor 10074-G5 treatment leads to 2-fold increase in murine LSKCD34low HSC compartment post 7 days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180905100608DOI Listing
September 2018
1 Read
3.522 Impact Factor

Cathepsin L induces proangiogenic changes in human omental microvascular endothelial cells via activation of the ERK1/2 pathway.

Curr Cancer Drug Targets 2018 Aug 31. Epub 2018 Aug 31.

Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon EX1 2LU. United Kingdom.

Background: Metastasis still remains the major cause of therapeutic failure, poor prognosis and high mortality in epithelial ovarian cancer (EOC) patients. Previously, we showed that EOC cells secrete a range of factors with potential pro-angiogenic activity, in disease-relevant human microvascular omental endothelial cells (HOMECs), including the lysosomal protease cathepsin L (CathL). Thus, the aim of this study was to examine potential pro-proliferative and pro-migratory effects of CathL in HOMECs and the activated signalling pathways, and whether these proangiogenic responses are dependent on CathL-catalytic activity. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/165035/article
Web Search
https://benthamscience.com/journals/current-cancer-drug-targ
Web Search
http://www.eurekaselect.com/151172/article
Web Search
http://www.eurekaselect.com/165035/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666180831123951DOI Listing
August 2018
4 Reads

The evaluation of animal models in the development of anticancer agents : from preclinical to clinical tests.

Curr Cancer Drug Targets 2018 Aug 16. Epub 2018 Aug 16.

Cancer Metastasis Alert and Prevention Center, and Biopharmaceutical Photocatalysis, State Key Laboratory of Photocatalysis on Energy and Environment, Fuzhou University, Fuzhou 350002. China.

Background: one of the main reasons for the most of anticancer drugs fail in the late preclinical testing and early clinical trials is the differences in drug effects observed from animals and patients, and challenge has been to find a balance to reduce the inherent differences from species.

Objectives: the animal toxicological studies of anticancer agents are aimed at predicting a safe starting dose and dosage regimen for human clinical trials.

Method: relevant information and data were assimilated from manuscripts, congress publications, and online sources. Read More

View Article

Download full-text PDF

Source
http://www.eurekaselect.com/164724/article
Publisher Site
http://dx.doi.org/10.2174/1568009618666180817095331DOI Listing
August 2018
23 Reads
3.522 Impact Factor

Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein-Protein Interactions in Cancer: Mechanistic View.

Curr Cancer Drug Targets 2018 Aug 2. Epub 2018 Aug 2.

Department of Clinical Biochemistry, Faculty of Biological Sciences, University of Kashmir, Srinagar. India.

Protein-protein interactions (PPIs) drive major signalling cascades and play critical role in cell proliferation, apoptosis, angiogenesis and trafficking. Deregulated PPIs are implicated in multiple malignancies and represent the critical targets for treating cancer. Herein we discuss the key protein-protein interacting domains implicated in cancer notably PDZ, SH2, SH3, LIM, PTB, SAM and PH. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180803104631DOI Listing
August 2018
3 Reads
3.522 Impact Factor

Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions.

Curr Cancer Drug Targets 2018 Jul 23. Epub 2018 Jul 23.

Flinders Centre for Innovation in Cancer, Flinders University and Medical Centre, Bedford Park, Adelaide. Australia.

Prostate cancer (PCa) is the most frequent cancer in men. The evolution from local PCa to castration-resistant PCa, an end-stage of disease, is often associated with changes in genes such as p53, androgen receptor, PTEN, and ETS gene fusion products. Evidence is accumulating that repurposing of metformin (MET) and valproic acid (VPA) either when used alone, or in combination, with another therapy, could potentially play a role in slowing down PCa progression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180724111604DOI Listing
July 2018
4 Reads

Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer.

Curr Cancer Drug Targets 2019 ;19(1):74-80

Department of Breast Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China.

Background: Long non-coding RNAs play crucial roles in various biological activities and diseases. The role of long intergenic non-coding RNA01638 (linc01638) in breast cancer, especially in HER2-positive breast cancer, remains largely unknown.

Objective: To investigate the effect of linc01638 on tumorigenesis in HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180709163718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327113PMC
January 2019
16 Reads

Conjugation of phthalocyanine photosensitizer with poly(amidoamine) dendrimer: improved solubility, disaggregation and photoactivity against HepG2 cells.

Curr Cancer Drug Targets 2018 Jul 6. Epub 2018 Jul 6.

School of Pharmacy, University of Washington, WA. United States.

Objective:To improve solubility and to reduce aggregation, ZnPcC4 was conjugated to a third-generation polyamidoamine dendrimer with amino end group (G3-PAMAM-NH2), which acts as a novel photodynamic therapy (PDT) drug carrier system. Method:The phthalocyanines were synthesized by construction reaction. The nanodrug was obtained from the conjugation of ZnPcC4 to G3-PAMAM-NH2, using EDC and NHS as coupling agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180706164046DOI Listing
July 2018
13 Reads

A Comprehensive review on Ethnomedicinal, Pharmacological and Phytochemical Basis of Anticancer Medicinal Plants of Pakistan.

Curr Cancer Drug Targets 2018 Jul 6. Epub 2018 Jul 6.

Department of Pharmacology, College of Pharmacy, the University of Punjab, Lahore. Pakistan.

The widespread emergence of cancer and development of resistance to chemotherapeutic agents is increasing the interest of scientists in the use of ethnomedicinal preparations and isolated phytochemicals in the treatment and prevention of disease. Medicinal plants are used in Pakistan for prehistoric times. The present review was designed to identify anticancer plants of ethnomedicinal significance and to summarize the anticancer activities carried out on these medicinal plants to establish the pharmacological and phytochemical basis for their use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180706164536DOI Listing
July 2018
16 Reads
3.522 Impact Factor

Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.

Curr Cancer Drug Targets 2018 Jul 6. Epub 2018 Jul 6.

Rumbaugh Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, Florida. United States.

Focal adhesion kinase (FAK) is a non-receptor tyrosine kinase, which is an essential player in regulating cell migration, invasion, adhesion, proliferation, and survival. Its overexpression and activation have been identified in sixty-eight percent of epithelial ovarian cancer patients and this is significantly associated with higher tumor stage, metastasis, and shorter overall survival of these patients. Most recently, a new role has emerged for FAK in promoting resistance to taxane and platinum based therapy in ovarian and other cancers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180706165222DOI Listing
July 2018
7 Reads

Tumor-dependent effects of proteoglycans and various glycosaminoglycan synthesizing enzymes and sulfotransferases on patients' outcome.

Curr Cancer Drug Targets 2018 Jul 6. Epub 2018 Jul 6.

Institute of Medical Immunology, Martin Luther University Halle-Wittenberg, 06112 Halle/ Saale. Germany.

Background: The small leucine-rich proteoglycans (SLRPs) biglycan (BGN) and decorin (DCN) linked with sulfated glycosaminoglycan (GAG) chains exhibit oncogenic or tumor suppressive potentials depending on the cellular context and association with GAGs.

Objective: We hypothesized that structural alterations and expression levels of BGN, DCN and their associated chondroitin sulfate (CS) polymerizing enzymes, dermatan sulfate (DS) epimerases and various sulfatases might be correlated with the tumor (sub)type and patients' survival.

Methods: We acquired breast cancer (BC) and glioma patients' datasets from cBioPortal and R2 Genomics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180706165845DOI Listing
July 2018
19 Reads

Polyploid Giant Cancer Cells (PGCCs): The Evil Roots of Cancer.

Curr Cancer Drug Targets 2018 Jul 3. Epub 2018 Jul 3.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX. United States.

Polyploidy is associated with increased cell size and commonly found in a subset of adult organs and blastomere stage of human embryo. The polyploidy is formed through endoreplication or cell fusion to support specific need of development including earliest embryogenesis. Recent data demonstrated that polyploid giant cancer cells (PGCCs) may have acquired an activated early embryonic-like program in response to oncogenic and therapeutic stress to generate reprogrammed cancer cells for drug resistance and metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180703154233DOI Listing
July 2018
39 Reads

Formulation, pharmacokinetic evaluation and cytotoxicity of an enhanced-penetration paclitaxel nanosuspension.

Curr Cancer Drug Targets 2018 Jun 29. Epub 2018 Jun 29.

Institute of Materia Medica, School of Pharmacy, Henan University, Jinming Road, Kaifeng, 475004. China.

Background: Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of the insoluble drugs formulation. Paclitaxel (PTX) is a well-known BCS class IV drug with poor solubility and permeability. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180629150927DOI Listing
June 2018
16 Reads
3.522 Impact Factor

Challenges and opportunities from basic cancer biology for nanomedicine for targeted drug delivery.

Curr Cancer Drug Targets 2018 Jun 28. Epub 2018 Jun 28.

Cancer Metastasis Alert and Prevention Center, and Pharmaceutical Photocatalysis of State Key Laboratory of Photocatalysis on Energy and Environment, College of Chemistry, Fuzhou University, Fuzhou 350002. China.

Background: Effective cancer therapy is still a great challenge for modern medical research due to the complex underlying mechanisms of tumorigenesis and tumor metastasis, and the limitations commonly associated with currently used cancer therapeutic options. Nanotechnology has been implemented in cancer therapeutics with immense potential for improving cancer treatment.

Objectives: Through information about the recent advances regarding cancer hallmarks, we could comprehensively understand the pharmacological effects and explore the mechanisms of the interaction between the nanomaterials, which could provide opportunities to develop mechanism-based nanomedicine to treat human cancers through. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180628160211DOI Listing
June 2018
2 Reads

Interactions of vascular endothelial growth factor and p53 with miR-195 in thyroid carcinoma: possible therapeutic targets in aggressive thyroid cancers.

Curr Cancer Drug Targets 2018 Jun 28. Epub 2018 Jun 28.

Cancer Molecular Pathology, School of Medicine, Griffith University, Gold Coast, Queensland. Australia.

Background: The clinical pathological features as well as the cellular mechanisms of miR-195 have not been investigated in thyroid carcinoma.

Objective: The aim of this study is to identify the interactions of vascular endothelial growth factor (VEGF), p53 and miR-195 in thyroid carcinoma. The clinical and pathological features of miR-195 were also investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180628154727DOI Listing
June 2018
6 Reads

Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality.

Curr Cancer Drug Targets 2018 ;18(5):402-404

Department of Hematology National Cancer Institute G. Pascale Foundation Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156800961805180522072538DOI Listing
January 2018
2 Reads

Macrophage flipping from foe to friend: A matter of interest in breast carcinoma heterogeneity driving drug resistance.

Curr Cancer Drug Targets 2018 Jun 27. Epub 2018 Jun 27.

Cancer and Translational Research Lab, Dr. D. Y. Patil Biotechnology & Bioinformatics Institute, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra. India.

Tumor heterogeneity within various cancer types including breast carcinoma is pivotal in the manifestations of tumor hallmarks. Tumor heterogeneity is seen as a common landscape where intra-tumoral components including cellular and non-cellular factors create interface with outside environment that lead to the unique identity of a specific cancer type. Among various contributors to tumor heterogeneity, cellular heterogeneity immensely plays a role in drug resistance and relapse of cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568009618666180628102247DOI Listing
June 2018
20 Reads